Avita Medical stock
RCELNASDAQAvita Medical Inc., HealthcareISIN US05380C1027
47Score 47 out of 100, Weak
Price and trend
83 / 100
Price history
+329% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 128% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 8.2% below its 52-week high. Largest decline in 14 years: 94% (February 2020 to December 2025).
Chart figures for advanced users
- SMA 50$13.31
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.10
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.27
- The lowest closing price of the last twelve months.
- Resistance$17.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Avita Medical Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $500.03M, is number 79 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $71.61M (up 11.5% year on year) and a loss of $48.59M.
- For fiscal 2026, analysts expect on average revenue of $89.95M (up 25.6%) and adjusted earnings per share of −$0.92.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 420 of 702 in Healthcare, median 53.
- Our model puts fair value at $16.30, with the price 1% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 38.1% a year since 2019, Medical (Devices) median 13.8%.Growth 70
Weaknesses
- DilutionShare count up 37% since 2019.Capital allocation 18
- Loss-makingLoss of $36.12M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 95% a year over the last 12 months.Stability 22
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 44 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $10.87 and expensive above $32.60 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $13.22, at 7.8% it would be $20.94.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17% on the twelve months before. Revenue has grown strongly since 2006, at around 28% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating −59%, net −68%. Last 12 months: net −43%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 5 Nov 2026EPS reported −$0.20 (expected −$0.24)above expectations
Analyst estimates
- Earnings per share
- −$0.92+2.5%
- Revenue
- $89.95M+2.8%
- Earnings per share
- −$0.36+5.5%
- Revenue
- $111.5M+1.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +73.8%2026 revenue guidance raised to $86 million to $89 million from $80 million to $85 million (growth of 20% to 24%).
“With this sequential revenue growth for the second quarter, and $41 million in revenue for the first 6 months of 2026 we are increasing our revenue guidance for 2026 from $80 million to $85 million to now $86 million to $89 million This will represent growth for this year from the $71.6 million in revenue in 2025 in …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $128,589 in total.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Avita Medical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- MedistimMEDI.OL $604.15M81
- Tactile Systems TechnologyTCMD $600.81M68
- Anteris Technologies GlobalAVR $571.11M33
- Ion Beam ApplicationsIBAB.BR $555.09M58
- CellaVisionCEVI.ST $483.11M80
- Metall ZugMETN.SW $460.29M40
- Revenio GroupREG1V.HE $419.17M47
- NeuroPaceNPCE $412.58M32
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2023)
- Valuation signal Fairly valued since 13 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.